{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:18:05Z","timestamp":1783487885086,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Intorduction<\/jats:title>\n                    <jats:p>Baricitinib (BARI), the selective JAK1\/JAK2 inhibitor demonstrates enhanced immunological activity against several inflammatory conditions. Given the complex, multiple pathogeneses of acute liver inflammatory injury (ALIs), this study investigates BARI in a non-sterile murine model of fulminant hepatic failure to address existing management gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mice were exposed to a toxic challenge with a single dose of lipopolysaccharide (LPS, 80 \u03bcg\/kg, ip) and D-galactosamine (D-GaIN, 800 mg\/kg, ip) on day 3. BARI (10 and 20 mg\/kg, po) were administered prophylactically from day 1 to day 3 with the last dose of BARI given 2 h before LPS\/D-GaIN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Investigations revealed substantial lowering in liver function indices in BARI-treated groups after the pathogenic elevation in the LPS\/D-GaIN group. These results coincided with remarkable reduction of necrosis and an improvement of hepatic architecture identified by the H&amp;amp;E staining in the BARI-treated groups compared to the disrupted histological features with substantial infiltration of inflammatory cells. The inflammatory cells observed in the LPS\/ D-GaIN group represent a major source of ROS that contributes to nitrosative stress via the respiratory burst (NO), peroxidation of the PUFA of the cell membrane (MDA), and consumption of the cellular antioxidant molecules (TAC). This oxidative condition was reversed in BARI groups together with reestablishment of the antioxidant axis of Nrf2\/HO-1 showing a remarkable capacity to restore redox equilibrium. The observed ameliorative potential of BARI is probably attributed to inhibition of IL-6 transcription, as confirmed by the inhibited activation of the transcription factor NF-\u03baB, with subsequent inhibition of JAK2\/STAT3. While curbing apoptosis as evidenced by reduced levels of cleaved caspase-3, BARI presented its ability to preserve the level of PI3K\/AKT\/ mTOR signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings highlight the protective capacity of BARI and its value for repurpose in medical management of acute liver failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1848559","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:48:56Z","timestamp":1783486136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The protective efficacy of baricitinib against lipopolysaccharide \/ D-Galactosamine\u2013Induced acute liver Injury"],"prefix":"10.3389","volume":"17","author":[{"given":"Khalid Khalaf","family":"Almutairi","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University","place":["Mansoura, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Hazem","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University","place":["Mansoura, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada M.","family":"Suddek","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University","place":["Mansoura, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/gg.2023.201045.1001","article-title":"Liver diseases among Arab world, current state and unmet needs, a scoping review","volume":"1","author":"Almansoury","year":"2023","journal-title":"Glob. Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/2050640620924157","article-title":"Liver injury in COVID-19: the current evidence","volume":"8","author":"Alqahtani","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.jhep.2014.12.016","article-title":"Acute liver failure: a curable disease by 2024?","volume":"62","author":"Bernal","year":"2015","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1324892","DOI":"10.3389\/fphar.2024.1324892","article-title":"Off-label use of baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K\/Akt\/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B6","first-page":"55","article-title":"Autoimmune hepatitis\u2013approach to diagnosis","volume":"8","author":"Czaja","year":"2006","journal-title":"Medscape Gen. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev-pharmtox-010818-021856","article-title":"Modulating NRF2 in disease: timing is everything","volume":"59","author":"Dodson","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0960327117689910","article-title":"Modulation of d-galactosamine\/lipopolysacharride\u2013induced fulminant hepatic failure by nilotinib","volume":"37","author":"El-Agamy","year":"2018","journal-title":"Hum. Exp. Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e18116","DOI":"10.1111\/jcmm.18116","article-title":"Nrf2\/HO\u20101, NF\u2010\u03baB and PI3K\/Akt signalling pathways decipher the therapeutic mechanism of pitavastatin in early phase liver fibrosis in rats","volume":"28","author":"Elbaset","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s10787-022-01058-z","article-title":"Escin suppresses immune cell infiltration and selectively modulates Nrf2\/HO-1, TNF-\u03b1\/JNK, and IL-22\/STAT3 signaling pathways in concanavalin A-induced autoimmune hepatitis in mice","volume":"30","author":"Elshal","year":"2022","journal-title":"Inflammopharmacology"},{"key":"B11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/9781119251316.ch17","article-title":"Acute liver failure","volume-title":"Schiff's Diseases of the Liver","author":"Fontana","year":"2017"},{"key":"B12","doi-asserted-by":"publisher","first-page":"809952","DOI":"10.3389\/fcell.2021.809952","article-title":"Dissecting the crosstalk between Nrf2 and NF-\u03baB response pathways in drug-induced toxicity","volume":"9","author":"Gao","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.intimp.2017.03.003","article-title":"Antioxidation, anti-inflammation and anti-apoptosis by paeonol in LPS\/d-GalN-induced acute liver failure in mice","volume":"46","author":"Gong","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-\u03baB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"112894","DOI":"10.1016\/j.intimp.2024.112894","article-title":"Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation","volume":"140","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","article-title":"Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism","volume":"73","author":"Loboda","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu. Review Pharmacol. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13075-024-03354-1","article-title":"Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6\/JAK\/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons","volume":"26","author":"Makabe","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1093\/rheumatology\/kead013","article-title":"Inhibitory effect of baricitinib on microglia and STAT3 in a region with a weak blood\u2013brain barrier in a mouse model of rheumatoid arthritis","volume":"62","author":"Matsushita","year":"2023","journal-title":"Rheumatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver Disease\u2014Clinical and diagnostic relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e12697","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence\u2010predicted testing in COVID\u201019 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"eabe4724","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci. Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/hep.0000000000000458","article-title":"Future directions in acute liver failure","volume":"78","author":"Stravitz","year":"2023","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/0006-2952(89)90208-6","article-title":"Tumor necrosis factor is a terminal mediator in galactosamine\/endotoxin-induced hepatitis in mice","volume":"38","author":"Tiegs","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"B30","first-page":"362","article-title":"Management of acute liver failure: update 2022","volume-title":"Seminars in Liver Disease, 2022","author":"Tujios","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice","volume":"10","author":"Villanueva-Paz","year":"2021","journal-title":"Antioxidants"},{"key":"B32","doi-asserted-by":"publisher","first-page":"108159","DOI":"10.1016\/j.intimp.2021.108159","article-title":"Isoliquiritigenin alleviates LPS\/D-GalN-induced acute liver failure by activating the PGC-1\u03b1\/Nrf2 pathway to reduce oxidative stress and inflammatory response","volume":"100","author":"Wang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e22505","DOI":"10.1096\/fj.202200543RRR","article-title":"Curcumin activates Nrf2\/HO\u20101 signaling to relieve diabetic cardiomyopathy injury by reducing ROS in vitro and in vivo","volume":"36","author":"Wu","year":"2022","journal-title":"FASEB J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1002\/fsn3.2459","article-title":"Protective effect of salidroside on hypoxia\u2010related liver oxidative stress and inflammation via Nrf2 and JAK2\/STAT3 signaling pathways","volume":"9","author":"Xiong","year":"2021","journal-title":"Food Sci. Nutr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1848559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:49:04Z","timestamp":1783486144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1848559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1848559"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1848559","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1848559"}}